StockData
Neogen Corp logo

Neogen Corp (NEOG) company profile

NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Aug 31, 2026Last filing: 10-Q on Oct 7, 2026Score 7/3049% above fair value
$10.90+0.02 (+0.18%)

Close on Nov 17, 2026Market cap $2.38BP/E –Yield –

About Neogen

In Vitro & In Vivo Diagnostic Substances, SIC 2835

Neogen Corporation develops, manufactures, and markets food and animal safety products and services. The Food Safety segment provides diagnostic test kits, culture media, and data management software to detect pathogens, toxins, allergens, and spoilage organisms, serving food and feed processors, agricultural operations, and regulatory agencies. The Animal Safety segment provides veterinary instruments, animal care products, pharmaceuticals, pest control solutions, and genomics testing services to livestock producers, veterinarians, and retailers.

The company operates globally, maintaining facilities in twenty-eight countries outside the United States, alongside distributors across more than one hundred countries. It conducts manufacturing and genomics laboratory services across facilities in the United States, the United Kingdom, Ireland, Brazil, Australia, China, and Canada. Neogen Corporation is headquartered in Lansing, Michigan.

Summary of the business section of Neogen's latest annual report, written by StockData.

Company profile

Company

Legal name
Neogen Corp
Founded
1981
Headquarters
Lansing, MI
Address
620 Lesher Place 48912
Phone
(517) 372-9200
Website
neogen.com
Employees
2,636, May 31, 2026
Industry
In Vitro & In Vivo Diagnostic Substances
Incorporated in
Michigan
Fiscal year ends
May 31
Auditor
BDO USA, P.C., Grand Rapids, MI

Stock & identifiers

Ticker
NEOG
Exchange
Nasdaq
IPO date
Aug 23, 1989
Shares outstanding
218M, Aug 31, 2026
Public float
$972.14M, Nov 30, 2025
Filer category
Large accelerated filer
Stock splits
2-for-1, Jun 7, 2021; 4-for-3, Dec 29, 2017; 3-for-2, Oct 31, 2013; 3-for-2, Dec 16, 2009; 3-for-2, Sep 5, 2007; 5-for-4, Jan 2, 2004
SEC CIK
711377
CUSIP
640491106
ISIN
US6404911066
FIGI
BBG000C1BCK2
Share class FIGI
BBG001S67B47
LEI
549300HJT9FC36N4UW43
EIN
38-2367843

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Mikheal NassifCEO, Director27,234
Jeremy YarwoodChief Scientific Officer297
Joe B. FreelsChief Commercial Officer6,345
Kevin M. BurkeChief HR Officer12,929
Gregory S. HastingsVP, Animal Health33,449
James A. WalterSVP of Manufacturing28,955
John Patrick MoylanChief Accounting Officer29,331
Richard Bryan RiggsbeeCFO51,502
Jennifer Evans StaceyChief Legal Officer38,627
Tamara A. RanalliSenior Vice President25,751
Amy M. RocklinFormer Chief Legal Officer82,182
David H. NaemuraFormer CFO93,936
John Edward AdentFormer CEO371,608
Douglas Edward JonesFormer COO104,362
Catherine E. WotekiDirector29,507
Rafael A. RodriguezDirector31,211
Aashima GuptaDirector38,180
Ronald D. GreenDirector29,044
James C. BorelDirector106,737
Jeffrey D. CapelloDirector42,892
Andrea F. WainerDirector11,834
Avi PelossofDirector9,804
William T. BoehmDirector47,913
James P. TobinDirector43,347
Thierry BernardDirector19,769

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2026
Adent
$3.14M$841.55K$2.66M$19$96
FY2026
Nassif
$8.69M$14.01M$2.66M$19$96
FY2025
Adent
$6.82M-$457.68K$2.24M$13$79
FY2025
Nassif
$0$0$2.24M$13$79
FY2024
Adent
$7.22M$4.50M$2.99M$29$84
FY2024
Nassif
$0$0$2.99M$29$84

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2026

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Mike Nassif
President & Chief Executive Officer
$630.77K$500.00K$3.25M$3.25M$1.00M$63.15K$8.69M–
Tamara A. Ranalli
Senior Vice President and General Manager, Global Food Safety
$188.46K$350.00K$750.00K$750.00K$99.32K$11.07K$2.15M–
R. Bryan Riggsbee
Senior Vice President & Chief Financial Officer
$334.62K$250.00K$1.13M$1.13M$480.00K$24.44K$3.34M–
Jennifer Evans Stacey
Senior Vice President & Chief Legal and Compliance Officer and Board Secretary
$63.46K–$375.00K$375.00K–$1.50K$814.96K–
John E. Adent
(Former) President & Chief Executive Officer
$358.27K–––$337.32K$2.44M$3.14M-54%
David H. Naemura
(Former) Chief Financial Officer & Operating Officer
$395.00K$325.00K$1.55M$1.70M$325.00K$15.60K$4.31M+61%
Amy M. Rocklin
(Former) Chief Legal & Administrative Officer
$388.50K$50.00K$898.00K$1.02M$227.50K$85.66K$2.67M+51%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of May 31, 2026, we employed 2,636 people worldwide, with 1,346 located in North America and 1,290 international.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jan 10, 2025Late filingNotification of late filing
Jul 31, 2023Late filingNotification of late filing
Sep 1, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 18, 2022Merger voteDefinitive merger proxy statement
Mar 17, 2022MergerRegistration of securities for a merger or exchange offer (S-4)
Dec 3, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 22, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 7, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 27, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 2, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 3, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 29, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 30, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 27, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 2, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 1, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 14, 2014Auditor changeChange in certifying accountant (8-K Item 4.01)
Jan 7, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 1, 2013Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 2, 2013Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 1, 2010Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 1, 2009Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 1, 2008Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 4, 2007Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 29, 2007Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 21, 2006Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 30, 2005Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 21, 2005Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)

See a number that looks wrong?